Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.

Excimer laser trabeculostomy (ELT), a laser-based MIGS procedure with no implants, enables consistent intraocular pressure-lowering in glaucoma patients over 8 years, both stand-alone and combined with phacoemulsification

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Moderated Poster Session: Miscellaneous
Session Date/Time: Saturday 11/02/2017 | 13:00-14:15
Paper Time: 13:08
Venue: Poster Area

First Author: M. Berlin USA
Co Author(s): M. Toeteberg-Harms  V. Roka  L. Kleineberg  R. Stodtmeister  M. Riggs  U. Giers  

Abstract Details


To evaluate the long-term intraocular pressure lowering efficacy and safety of Excimer Laser Trabeculostomy (ELT), both as a stand-alone procedure and combined with phacoemulsification (ELT+Phaco) in patients with open-angle glaucoma (OAG).


Augen Laser Klinik, Detmold, Germany


46 eyes with open angle glaucoma or ocular hypertension treated medically underwent ab-interno Excimer Laser Trabeculostomy. 37 eyes with open angle glaucoma or ocular hypertension treated medically with surgical cataract underwent ELT combined with phacoemulsification. Patients were followed at 1 day, 1 month, 3 months, 6 months, 1 year, and every year thereafter until 8 years from initial treatment. The primary outcome measures are mean change in IOP (without washout) and number of glaucoma medications from baseline. Secondary outcome measures are change in visual acuity (BCVA), surgical complications, and adverse events (AE).


At 8 years, the mean IOP in the ELT group was reduced by 29.7% from a pre-op IOP of 22.9±5.4mmHg to 16.1±3.4mmHg (p-value IOP <0.001). In the ELT+Phaco group, the mean IOP was reduced by 43.4% from a pre-op IOP of 25.1±6.1mmHg to 14.2±3.1mmHg (p-value IOP <0.001). The number of glaucoma medications at 8 years for the ELT group was 1.2±1.2 medications compared to 1.6±0.7 medications at pre-op (p-value meds 0.152). The number of medications for the ELT+Phaco group was 1.8±0.8 medications compared to 1.3±0.7 medications at pre-op (p-value meds 0.087).


ELT both as a stand-alone MIGS procedure and ELT+Phaco are clinically safe and effective and enable long-term, consistent, significant reductions in IOP in patients with OAG. Glaucoma medication requirements decreased with ELT alone and were similar to pre-op in ELT+Phaco with marked, consistent, significant IOP lowering. 8-year post-ELT IOP reduction with no implants was equivalent to 1- & 5-year IOP-lowering data following combined phacoemulsification with iStent implants. This study presents the longest post MIGS procedure data which validates the concept of MIGS procedures for long-term IOP lowering.

Financial Disclosure:


Back to previous